SCHEMBL4570339

SCHEMBL4570339

C=CCOC1CCC(C2CCC(OCC=C)CC2)CC1

nearest known ligand 0.41

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.41
ALDH1A1 P00352 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3933914 0.92
SCHEMBL472084 0.92 EPHX2 (0.44) EPHX2ALDH1A1
SCHEMBL19339306 0.91 EPHX2 (0.37) EPHX2
SCHEMBL9508640 0.91 EPHX2 (0.37) EPHX2
SCHEMBL9508628 0.91 EPHX2 (0.37) EPHX2
SCHEMBL19339276 0.91 EPHX2 (0.37) EPHX2
SCHEMBL9508619 0.91 EPHX2 (0.37) EPHX2
SCHEMBL10973620 0.89 EPHX2 (0.36) EPHX2
SCHEMBL10452740 0.89 EPHX2 (0.36) EPHX2
SCHEMBL10973624 0.89 EPHX2 (0.36) EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9793456-B2 Molded resin body for surface-mounted light-emitting device, manufacturing method thereof, and surface-mounted light-emitting device KANEKA CORPORATION (JP) 2017-10-17 US disclosed
US-9793456-B2 Molded resin body for surface-mounted light-emitting device, manufacturing method thereof, and surface-mounted light-emitting device KANEKA CORPORATION (JP) 2017-10-17 US disclosed
US-9496468-B2 Curable resin composition, curable resin composition tablet, molded body, semiconductor package, semiconductor component and light emitting diode KANEKA CORPORATION (JP) 2016-11-15 US disclosed
US-9496468-B2 Curable resin composition, curable resin composition tablet, molded body, semiconductor package, semiconductor component and light emitting diode KANEKA CORPORATION (JP) 2016-11-15 US disclosed
EP-2216336-B1 PROCESS FOR PRODUCTION OF CYCLIC POLYORGANOSILOXANE, CURING AGENT, CURABLE COMPOSITION, AND CURED PRODUCT OF THE CURABLE COMPOSITION KANEKA CORP (JP) 2015-11-04 EP disclosed
US-9178120-B2 Curable resin composition, curable resin composition tablet, molded body, semiconductor package, semiconductor component and light emitting diode KANEKA CORPORATION (JP) 2015-11-03 US disclosed
US-9178120-B2 Curable resin composition, curable resin composition tablet, molded body, semiconductor package, semiconductor component and light emitting diode KANEKA CORPORATION (JP) 2015-11-03 US disclosed
US-20150188008-A1 CURABLE RESIN COMPOSITION, CURABLE RESIN COMPOSITION TABLET, MOLDED BODY, SEMICONDUCTOR PACKAGE, SEMICONDUCTOR COMPONENT AND LIGHT EMITTING DIODE KANEKA CORPORATION (JP) 2015-07-02 US disclosed
US-20150188008-A1 CURABLE RESIN COMPOSITION, CURABLE RESIN COMPOSITION TABLET, MOLDED BODY, SEMICONDUCTOR PACKAGE, SEMICONDUCTOR COMPONENT AND LIGHT EMITTING DIODE KANEKA CORPORATION (JP) 2015-07-02 US disclosed
US-20150008455-A1 MOLDED RESIN BODY FOR SURFACE-MOUNTED LIGHT-EMITTING DEVICE, MANUFACTURING METHOD THEREOF, AND SURFACE-MOUNTED LIGHT-EMITTING DEVICE KANEKA CORPORATION (JP) 2015-01-08 US disclosed
US-20100267919-A1 PROCESS FOR PRODUCTION OF CYCLIC POLYORGANOSILOXANE, CURING AGENT, CURABLE COMPOSITION, AND CURED PRODUCT OF THE CURABLE COMPOSITION KANEKA CORPORATION (JP) 2010-10-21 US disclosed
US-20100267919-A1 PROCESS FOR PRODUCTION OF CYCLIC POLYORGANOSILOXANE, CURING AGENT, CURABLE COMPOSITION, AND CURED PRODUCT OF THE CURABLE COMPOSITION KANEKA CORPORATION (JP) 2010-10-21 US disclosed
US-20100222525-A1 CURABLE COMPOSITION KANEKA CORPORATION (JP) 2010-09-02 US disclosed
US-20100222525-A1 CURABLE COMPOSITION KANEKA CORPORATION (JP) 2010-09-02 US disclosed
US-7785715-B2 Compound with at least two carbon-carbon double bonds such as triallyl isocyanurate; compound with SiH groups such as reaction product of 1,3,5,7 tetramethylcyclotetrasiloxane and triallyl isocyanurate; coupler; and not less than 5% by weight of rutile TiO2 KANEKA CORPORATION (JP) 2010-08-31 US disclosed
US-7785715-B2 Compound with at least two carbon-carbon double bonds such as triallyl isocyanurate; compound with SiH groups such as reaction product of 1,3,5,7 tetramethylcyclotetrasiloxane and triallyl isocyanurate; coupler; and not less than 5% by weight of rutile TiO2 KANEKA CORPORATION (JP) 2010-08-31 US disclosed
EP-2216336-A1 PROCESS FOR PRODUCTION OF CYCLIC POLYORGANOSILOXANE, CURING AGENT, CURABLE COMPOSITION, AND CURED PRODUCT OF THE CURABLE COMPOSITION Kaneka Corporation (JP) 2010-08-11 EP disclosed
EP-1967540-A1 CURABLE COMPOSITION Kaneka Corporation (JP) 2008-09-10 EP disclosed
US-7371462-B2 1,3,5,7-tetramethylcyclotetrasiloxane and triallyl isocyanurate, a hydrosilylation catalyst, a silane coupling agent and/or an epoxy group-containing compound, and a silanol condensation catalyst KANEKA CORPORATION (JP) 2008-05-13 US disclosed
US-7371462-B2 1,3,5,7-tetramethylcyclotetrasiloxane and triallyl isocyanurate, a hydrosilylation catalyst, a silane coupling agent and/or an epoxy group-containing compound, and a silanol condensation catalyst KANEKA CORPORATION (JP) 2008-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267919-A1 PROCESS FOR PRODUCTION OF CYCLIC POLYORGANOSILOXANE, CURING AGENT, CURABLE COMPOSITION, AND CURED PRODUCT OF THE CURABLE COMPOSITION SMCHD1, SQLE, SMARCA5 EPHX2 79/4885ALDH1A1 1525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.